<DOC>
	<DOCNO>NCT01276119</DOCNO>
	<brief_summary>To evaluate safety , tolerability , blood level effect CDP6038 administer intravenous infusion ( iv ) subcutaneous ( sc ) injection .</brief_summary>
	<brief_title>The First Clinical Study Test Safety , Blood Levels Other Effects CDP6038 Healthy Males</brief_title>
	<detailed_description />
	<criteria>Body mass index 19.0 28.0 kg/m² body weight ≥ 50 kg ≤ 120 kg Previous trial participation blood donation/loss within 3 month Subject healthy ( eg significant medical history , take drug treatment , psychological emotional problem , drug alcohol abuse ( current historical ) Plans actual vaccination within 3 month Previous drug treatment Tobacco use heavy caffeine consumption Systolic blood pressure &lt; 90 &gt; 145mmHg , diastolic blood pressure &lt; 40 &gt; 90mmHg heart rate &lt; 45 &gt; 90 beat per minute</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>CDP6038</keyword>
	<keyword>single-dose</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>healthy subject</keyword>
</DOC>